Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Apricus Biosc Inc (APRI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 13,153
  • Shares Outstanding, K 12,770
  • Annual Sales, $ 5,760 K
  • Annual Income, $ -7,430 K
  • 36-Month Beta 0.69
  • Price/Sales 2.24
  • Price/Cash Flow 0.00
  • Price/Book 0.00

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.95 +9.47%
on 05/02/17
1.30 -20.00%
on 04/24/17
-0.16 (-13.33%)
since 04/21/17
3-Month
0.95 +9.47%
on 05/02/17
3.41 -69.50%
on 03/09/17
-2.10 (-66.88%)
since 02/22/17
52-Week
0.95 +9.47%
on 05/02/17
6.00 -82.67%
on 06/23/16
-2.76 (-72.63%)
since 05/20/16

Most Recent Stories

More News
Apricus Biosciences Provides Corporate Update and First Quarter 2017 Financial Results

Vitaros U.S. NDA Re-Submission Remains on Track for Third Quarter 2017

APRI : 1.04 (+0.97%)
Apricus Biosciences Provides Corporate Update and First Quarter 2017 Financial Results

Vitaros U.S. NDA Re-Submission Remains on Track for Third Quarter 2017

APRI : 1.04 (+0.97%)
Apricus Biosciences Announces the Initiation of Vitaros Drug-Device Human Factors Study

SAN DIEGO, May 04, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today reported that the Vitaros...

APRI : 1.04 (+0.97%)
Apricus Biosciences Announces Corporate Update and First Quarter 2017 Financial Results Conference Call

Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that Apricus' first quarter 2017 financial results will...

APRI : 1.04 (+0.97%)
Apricus Biosciences Announces Corporate Update and First Quarter 2017 Financial Results Conference Call

SAN DIEGO, May 04, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that Apricus'...

APRI : 1.04 (+0.97%)
Apricus Biosciences Regains Compliance with Nasdaq Continued Listing Requirements

Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that on May 2, 2017, Apricus was notified by The NASDAQ...

APRI : 1.04 (+0.97%)
Apricus Biosciences Regains Compliance with Nasdaq Continued Listing Requirements

SAN DIEGO, May 02, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that on May...

APRI : 1.04 (+0.97%)
Apricus Biosciences and Protalix Biotherapeutics Seeing Opposite Sides of FDA Clinical Trials

NEW YORK, NY / ACCESSWIRE / April 13, 2017 / These two companies are finding the FDA trial process to be less predictable than anticipated. Apricus has investors optimistic, while Protalix is putting...

APRI : 1.04 (+0.97%)
Drug Makers Stocks Under Scanner -- Synergy Pharma, Novo Nordisk, Apricus Biosciences, and Sucampo Pharma

Stock-Callers.com has issued research reports on four Drug Manufacturers stocks, which are: Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), Novo Nordisk A/S (NYSE: NVO), Apricus Biosciences Inc. (NASDAQ:...

SCMP : 10.65 (+0.95%)
NVO : 41.50 (+1.59%)
APRI : 1.04 (+0.97%)
SGYP : 3.93 (+0.26%)
Apricus Biosciences Announces Corporate Update, Fourth Quarter and Full Year 2016 Financial Results Conference Call

Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that the Company's fourth quarter and full year 2016 financial...

APRI : 1.04 (+0.97%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Apricus Bio operates in the pharmaceutical industry and focuses on research and development in the area of drug delivery. Its proprietary drug delivery technology is called NexACT '. Backed by revenue generating CRO business, Bio-Quant, Inc. and its NexMed USA subsidiary, Apricus Bio has leveraged the...

See More

Support & Resistance

2nd Resistance Point 1.11
1st Resistance Point 1.07
Last Price 1.04
1st Support Level 1.00
2nd Support Level 0.97

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.